ABBV

Abbvie Inc

Apr 09 • 04:00PM ET

212.40

+0.81 0.38 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM IWF VHT

Index	S&P 500	P/E	89.95	EPS (ttm)	2.36	Insider Own	0.13%	Shs Outstand	1.77B	Perf Week	-1.20%
Market Cap	375.56B	Forward P/E	13.14	EPS next Y	16.17	Insider Trans	-1.97%	Shs Float	1.77B	Perf Month	-6.44%
Enterprise Value	438.53B	PEG	0.62	EPS next Q	2.92	Inst Own	75.69%	Short Float	1.42%	Perf Quarter	-9.01%
Income	4.19B	P/S	6.14	EPS this Y	44.75%	Inst Trans	1.38%	Short Ratio	3.49	Perf Half Y	-8.77%
Sales	61.16B	P/B	-	EPS next Y	11.68%	ROA	3.11%	Short Interest	25.11M	Perf YTD	-7.04%
Book/sh	-1.85	P/C	71.44	EPS next 5Y	21.30%	ROE	15221.82%	52W High	244.81 -13.24%	Perf Year	18.10%
Cash/sh	2.97	P/FCF	21.08	EPS past 3/5Y	-29.11% -2.81%	ROIC	7.43%	52W Low	164.39 29.20%	Perf 3Y	31.48%
Dividend Est.	6.82 (3.21%)	EV/EBITDA	15.51	Sales past 3/5Y	1.75% 5.95%	Gross Margin	70.12%	Volatility	2.87% 2.56%	Perf 5Y	97.51%
Dividend TTM	6.65 (3.13%)	EV/Sales	7.17	EPS Y/Y TTM	-1.34%	Oper. Margin	32.81%	ATR (14)	5.70	Perf 10Y	263.26%
Dividend Ex-Date	Apr 15, 2026	Quick Ratio	0.56	Sales Y/Y TTM	8.57%	Profit Margin	6.84%	RSI (14)	46.67	Recom	1.79
Dividend Gr. 3/5Y	5.21% 6.56%	Current Ratio	0.67	EPS Q/Q	5724.31%	SMA20	0.30%	Beta	0.35	Target Price	254.88
Payout	281.66%	Debt/Eq	-	Sales Q/Q	10.04%	SMA50	-3.76%	Rel Volume	0.62	Prev Close	211.59
Employees	57000	LT Debt/Eq	-	Earnings	Apr 29 BMO	SMA200	-1.96%	Avg Volume	7.19M	Price	212.40
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.15% 1.25%	Trades		Volume	4,458,507	Change	0.38%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$260
Feb-20-26	Initiated	Barclays	Overweight	$275
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral	$240
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy	$265
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$280
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203

Show Previous Ratings

Apr-08-26 08:00AM	BOTOX Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year (PR Newswire)
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
09:53AM	The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it. (MarketWatch)
09:00AM	Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin (PR Newswire)
Apr-02-26 03:39PM	Trump Slaps 100% Tariffs on Some Drug Imports. What to Know. (Barrons.com)
04:36PM	Loading…
Mar-31-26 04:36PM	US Corporate Taxes Drop $65 Billion After Trump's $3.4 Trillion Tax Law (GuruFocus.com)
08:05AM	Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting (PR Newswire)
08:00AM	AbbVie to Host First-Quarter 2026 Earnings Conference Call (PR Newswire)
06:00AM	Trumps Tax Cut Delivers at Least $65 Billion Windfall to Corporations (Bloomberg)
Mar-30-26 08:00AM	Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD) (PR Newswire)
Mar-27-26 10:00AM	AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting (PR Newswire)
01:01AM	ABBV- An Attractive Income Stock in this Turbulent Market (MoneyShow)
Mar-26-26 04:00AM	Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC) (PR Newswire)
03:00AM	Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVEDERM at AMWC Monaco (PR Newswire)
Mar-24-26 08:00AM	AbbVie Named Official Pharmaceutical Partner of Major League Baseball (PR Newswire)
11:39AM	Loading…
Mar-19-26 11:39AM	Long-only funds are buying non-US stocks, BofA says (Investing.com)
03:00AM	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions (PR Newswire)
Mar-18-26 08:05AM	J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections (BioPharma Dive) -5.20%
Mar-12-26 04:51PM	Why Investors Aren't Fleeing to Safe-Haven Stocks (The Wall Street Journal)
08:48AM	UCBs Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical (Clinical Trials Arena)
Mar-11-26 05:33AM	Bimzelx tops Skyrizi in head-to-head psoriatic arthritis trial (BioPharma Dive)
Mar-10-26 07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 10:11AM	AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss (Benzinga)
09:50AM	Here's Why AbbVie (ABBV) is a Strong Momentum Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:10AM	Quiet Outperformance From an Overlooked Dividend ETF (MarketBeat)
08:00AM	AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults (PR Newswire)
04:46AM	AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn's Disease (Insider Monkey)
12:39AM	1 Momentum Stock to Consider Right Now and 2 We Ignore (StockStory)
Mar-08-26 09:54AM	Retirees Take Note: DGRO Yields 2.4%, Has Raised Its Dividend Every Single Year for Over a Decade (24/7 Wall St.)
09:00AM	Loading…
09:00AM	This 5-Star ETF Pays Monthly Dividends and Has Never Missed in 19 Years (24/7 Wall St.)
Mar-06-26 03:48PM	Jobs Report Just Dented Most Bulletproof Sector ETF In The Market (Benzinga)
11:30AM	AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? (Zacks)
08:25AM	These 3 Cash Flow Machines Provide Stability in Uncertain Markets (MarketBeat)
08:21AM	Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? (Zacks)
07:39AM	Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? (Zacks)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 11:02PM	AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
05:45PM	AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
Mar-04-26 08:00AM	ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS (PR Newswire)
Mar-03-26 01:27PM	OSE narrows pipeline focus amid Boehringer MASH collaboration retreat (Pharmaceutical Technology)
08:00AM	AbbVie to Present at the Leerink Partners Global Healthcare Conference (PR Newswire)
Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
12:28PM	AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson (Benzinga)
08:30AM	AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease (PR Newswire)
02:57AM	Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? (Insider Monkey)
Feb-27-26 09:40AM	Why AbbVie (ABBV) is a Top Value Stock for the Long-Term (Zacks)
Feb-26-26 10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
Feb-25-26 09:24PM	RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears (Insider Monkey)
03:29PM	Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference (MarketBeat)
09:57AM	Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie (Investing.com)
08:01AM	Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested (Benzinga)
07:57AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More (24/7 Wall St.)
Feb-24-26 04:57PM	AbbVie makes $380 million 'made in the U.S.' move (TheStreet)
10:29AM	Is AbbVie Stock Underperforming the Dow? (Barchart)
09:45AM	Here's Why AbbVie (ABBV) is a Strong Growth Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	AbbVie to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire)
06:01AM	AbbVie to spend $380M on two 2 manufacturing facilities in Illinois (Manufacturing Dive)
05:37AM	AbbVie announces $380m investment in North Chicago API facilities (Pharmaceutical Business Review)
02:11AM	FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL (Insider Monkey)
Feb-23-26 02:25PM	AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago (Chicago Tribune)
01:13PM	Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential (Insider Monkey)
11:00AM	AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States (PR Newswire)
11:00AM	AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago (Chicago Tribune)
10:35AM	Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings? (Zacks)
08:13AM	Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs (Zacks)
08:02AM	Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather (24/7 Wall St.)
Feb-20-26 10:57AM	Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now? (Zacks)
08:16AM	Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026? (Zacks)
08:08AM	Barclays launches U.S. biopharma coverage with four preferred picks (Investing.com)
08:02AM	FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer (Benzinga)
02:00AM	U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) (PR Newswire)
Feb-19-26 09:37AM	AbbVie Declares Quarterly Dividend (PR Newswire)
Feb-18-26 09:33PM	Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited (Insider Monkey)
03:08AM	The Zacks Analyst Blog AbbVie, RTX, International Business Machines, EVI Industries, and Rocky Mountain Chocolate Factory (Zacks)
Feb-17-26 11:32PM	1 Mega-Cap Stock on Our Watchlist and 2 We Avoid (StockStory)
04:13PM	Top Analyst Reports for AbbVie, RTX & IBM (Zacks)
Feb-16-26 09:50AM	Why AbbVie (ABBV) is a Top Momentum Stock for the Long-Term (Zacks)
07:05AM	AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus (MarketBeat)
Feb-13-26 06:01PM	Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio (GuruFocus.com)
09:57AM	Where is AbbVie Inc. (ABBV) Headed According to the Street? (Insider Monkey)
08:00AM	Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent (Investing.com)
Feb-12-26 12:37PM	This Is Gracos Dividend Score After Paying Investors (24/7 Wall St.)
10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
04:42AM	AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform (Insider Monkey)
Feb-11-26 07:49PM	Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable (Insider Monkey)
06:49PM	AbbVie sues US health agency over Botox price controls (Reuters)
06:39PM	Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa (MarketBeat)
12:35AM	The 5 Most Interesting Analyst Questions From AbbVie's Q4 Earnings Call (StockStory)
Feb-10-26 10:29AM	AbbVies $100bn deal aligns drug pricing with domestic manufacturing goals (Pharmaceutical Technology)
09:40AM	Here's Why AbbVie (ABBV) is a Strong Value Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:32AM	Here's What Will Drive AbbVie's Top-line Growth in 2026 (Zacks)
08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
Feb-09-26 09:24AM	J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss (Zacks)
09:11AM	Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? (Zacks)
Feb-08-26 11:41PM	3 Market-Beating Stocks to Research Further (StockStory)
Feb-06-26 01:52PM	CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder (Benzinga)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	233.56	5,230	1,221,519	2,654	Mar 06 05:05 PM
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	233.56	5,230	1,221,519		Mar 06 05:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	234.39	18,668	4,375,549	4,619	Mar 03 06:10 PM
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your Finviz experience